<DOC>
	<DOCNO>NCT01113671</DOCNO>
	<brief_summary>This biomarker exploratory study design investigate function oxidation high density lipoprotein ( HDL ) ( good cholesterol ) patient type 2 diabetes mellitus treat Vitamin E versus placebo segregate type Haptoglobin protein blood .</brief_summary>
	<brief_title>Type 2 Diabetes Haptoglobin Phenotype Vitamin E</brief_title>
	<detailed_description>There exist ample evidence support hypothesis vitamin E supplementation Hp 2-2 DM individual reduce incidence stroke , myocardial infarction cardiovascular death . Data regard association Hp 1-1 2-1 phenotype vitamin E treatment cardiovascular outcome MI , stroke CV death lacking . Furthermore data correlate Hp phenotype , vitamin E HDL function , structure oxidation . We wish evaluate effect vitamin E treatment diabetic patient type 2 diabetes HDL function , structure oxidation correlate parameter Hp phenotype . This study first study prospectively evaluate interaction Hp phenotype vitamin E type 2 diabetic patient . As wish evaluate surrogate marker reverse cholesterol transport evidence function dysfunction HDL relatively small scale study engage large scale clinical outcome study . Study objectives . To evaluate effect vitamin E treatment HDL function reverse cholesterol transport . Test product . Natural Source Vitamin E ( d-Î±-tocopherol ) 400IU administer P.O . soft gel capsule . Study population . The study population comprise men woman , age 55 type 2 DM . 90 DM individual comprise treatment phase study divide 30 patient Hp phenotype ( 1-1 , 2-1 , 2-2 ) . All 90 patient randomize double blind fashion two treatment group , Vitamin E Natural source 400IU per day versus match placebo assure equal amount patient phenotype allocate placebo Vitamin E. Study power Calculation_We calculate sample total 90 patient ( 30 phenotype ) require identify 30 % difference Reverse Cholesterol Transport group statistically significant interaction phenotype treatment , 80 % power two side p value &lt; 0.05 . Study administration . Eligible patient identify use ICARE study database help ICARE study coordinator Clalit Health Services . We identify patient 3 Hp phenotype ( patient Hp type part ICARE study Hp type file ) . We call patient ask question accord screen questioner identify eligible accord inclusion/exclusion criterion . Those eligible invited Technion faculty medicine recruit study agree sign Informed Consent Form ( ICF ) . Patients give blood sample 50cc blood enrollment serve baseline test reverse cholesterol transport well HDL structure oxidation . Patients randomize vitamin E placebo double blind manner . We recruit consecutive eligible patient ICARE registry till reach number 30 patient phenotype total 90 patient . For 90 treated patient Blood test ( 50cc blood ) perform 3 month treatment , cross additional 3 month treatment end last blood test perform ( 50cc ) . Patients participate treatment phase study arrive clinic 3 time ( baseline randomization visit , end first treatment visit end second treatment visit ) . Analysis . Reverse cholesterol transport result compare within group use pair unpaired student 's t-tests appropriate . The p interaction 3 phenotype group treatment also determine .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>1 . Male female age 55 . 2 . Ability communicate comply study requirement . 3 . Able understand content inform consent , provide write informed consent . 4 . Do take antioxidant vitamin drug include vitamin E , also include kind herbal medicine homeopathic medicine , patient take drug agree withdrawal drug eligible recruitment one month washout . 1 . Known allergy vitamin E. 2 . Active cardiovascular disease ( active stable/unstable angina , less one year post MI stroke prior randomization ) . 3 . Hematological ( hemoglobin &lt; 10 g/dL ) , hepatic ( aspartate aminotransferase alanine aminotransferase value &gt; 2 x upper limit normal ) , renal disease ( serum creatinine &gt; 2.5 mg/dL ) baseline . 4 . Platelet count &lt; 100,000 mm3 and/or abnormal prothrombin partial thromboplastin time baseline . 5 . Active inflammatory condition likely require intervention course study regard clinically meaningful investigator . 6 . Active treat malignancy within 12 month prior randomization exception basal cell squamous cell carcinoma . 7 . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion drug . 8 . Recent history ( within past 12 month ) alcohol substance abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 4 oz wine , 1.5 oz distil spirit ) . 9 . Female subject either postmenopausal one year surgically sterile , use effective contraceptive method barrier method spermicidal intrauterine device . 10 . History noncompliance medical regimen , subject unwilling comply study protocol . 11 . Administration antioxidant vitamin drug include vitamin E willing withdrawal washout one month prior enrollment . 12 . Administration investigational drug within 30 day plan enrollment study . criterion 3,4 determine use late blood test do health plan primary physician , patient ask supply result . criterion assess base patient telephone interview .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Diabetes Mellitus type 2</keyword>
	<keyword>Haptoglobin phenotype</keyword>
	<keyword>Vitamin E</keyword>
</DOC>